Nanoemulsions of sulfonamide carbonic anhydrase inhibitors strongly inhibit the growth of Trypanosoma cruzi

References

• Bern C. Chagas’ disease. New Engl J Med 2015;373:456–66.
   PubMed Web of Science ®Google Scholar
• Vermelho AB, Capaci GR, Rodrigues IA, et al. Carbonic anhydrases from Trypanosoma and Leishmania as anti-protozoan drug targets. Bioorg Med Chem 2017;25:1543–55.
   PubMed Web of Science ®Google Scholar
• Correia JPR, Costa ACD, Rocha EA, et al. Pharmacotherape-utic follow-up of patients with Chagas disease using benznidazole: drug-related problems and pharmaceutical interventions. Rev Soc Bras Med Trop 2017;50:334–40.
   PubMed Web of Science ®Google Scholar
• Franciso AF, Jayawardahna S, Lewis MD, et al. Biological factors that impinge on Chagas disease drug development. Parasitology 2017;3:1–10.
   Google Scholar
• Shah P, Bhalodia D, Shelat P. Nanoemulsions: preparation, structure, functional properties and their antimicrobial effects. Sys Rev Pharm 2016;3:E378. DOI:10.4103/0975-8453.59509
   Google Scholar
• de Campos VE, Ricci-Júnior E, Mansur CR. Nanoemulsions as delivery systems for lipophilic drugs. J Nanosci Nanotechnol 2012;12:2881–90.
   PubMed Web of Science ®Google Scholar
• Teixeira HF, Bruxel F, Fraga M, et al. Cationic nanoemulsions as nucleic acids delivery systems. Int J Pharm 2017;534:356–367.
   PubMed Web of Science ®Google Scholar
• Araujo SC, Mattos ACA, Teixeira HF, et al. Improvement of in vitro efficacy of novel schistomicidal drug by incorporation into nanoemulsions. Int J Pharm Pharmaceutical Nanotecnol 2007;337:307–315.
   Google Scholar
• Senna JP, Ricci-Júnior E, Mansur CRE. Development and evaluation of nanoemulsions containing phthalocyanines for use in photodynamic cancer therapy. J Nanosci Nanotechno 2015;6:4205–14.
   Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–81.
   PubMed Web of Science ®Google Scholar
• Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem 2016;31:345–60.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2012;27:759–72.
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Supuran CT, Carta F. Antiobesity carbonic anhydrase inhibitors: a literature and patent review. Expert Opin Ther Pat 2013;23:725–35.
   PubMed Web of Science ®Google Scholar
• (a) Nocentini A, Carta F, Ceruso M, et al. Click-tailed coumarins with potent and selective inhibitory action against the tumor-associated carbonic anhydrases IX and XII Bioorg. Med Chem 2015;23:6955–66.
   Web of Science ®Google Scholar
  (b) Puccetti L, Fasolis G, Vullo D, et al. Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with Schiff's bases incorporating chromone and aromatic sulfonamide moieties, and their zinc complexes. Bioorg Med Chem Lett 2005;15:3096–101.
   PubMed Web of Science ®Google Scholar
• Capasso C, Supuran CT. Sulfa and trimethoprim-like drugs–antimetabolites acting as carbonic anhydrase, dihydropteroate synthase and dihydrofolate reductase inhibitors. J Enzyme Inhib Med Chem 2014;29:379–87.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Capasso C. New light on bacterial carbonic anhydrases phylogeny based on the analysis of signal peptide sequences. J Enzyme Inhib Med Chem 2016;31:1254–60.
   PubMed Web of Science ®Google Scholar
• Capasso C, Supuran CT. An overview of the alpha-, beta- and gamma-carbonic anhydrases from bacteria: can bacterial carbonic anhydrases shed new light on evolution of bacteria? J Enzyme Inhib Med Chem 2015;30:325–32.
   PubMed Web of Science ®Google Scholar
• Capasso C, Supuran CT. Bacterial, fungal and protozoan carbonic anhydrases as drug targets. Expert Opin Ther Targets 2015;19:1689–704.
   PubMed Web of Science ®Google Scholar
• (a) Diaz JR, Fernández Baldo M, Echeverría G, et al. A substituted sulfonamide and its Co (II), Cu (II), and Zn (II) complexes as potential antifungal agents. J Enzyme Inhib Med Chem 2016;31: 51–62.
   PubMed Web of Science ®Google Scholar
  (b) Scozzafava A, Briganti F, Mincione G, et al. Carbonic anhydrase inhibitors: synthesis of water-soluble, aminoacyl/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route. J Med Chem 1999;42:3690–700.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Inhibition of carbonic anhydrase from Trypanosoma cruzi for the management of Chagas disease: an underexplored therapeutic opportunity. Future Med Chem 2016;8:311–24.
   PubMed Web of Science ®Google Scholar
• Prete SD, Vullo D, Fisher GM, et al. Discovery of a new family of carbonic anhydrases in the malaria pathogen Plasmodium falciparum—the η-carbonic anhydrases. Bioorg Med Chem Lett 2014;24:4389–96.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A, Mastrolorenzo A. Bacterial proteases: current therapeutic use and future prospects for the development of new antibiotics. Expert Opin Ther Pat 2001;11:221–59.
   Web of Science ®Google Scholar
• (a) Capasso C, Supuran CT. An overview of the selectivity and efficiency of the bacterial carbonic anhydrase inhibitors. Curr Med Chem 2015;22:2130–9.
   PubMed Web of Science ®Google Scholar
  (b) Carta F, Supuran CT. Diuretics with carbonic anhydrase inhibitory action: a patent and literature review (2005–2013). Expert Opin Ther Pat 2013;23:681–91.
   PubMed Web of Science ®Google Scholar
• Pan P, Vermelho AB, Capaci Rodrigues G, et al. Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease. J Med Chem 2013;56:1761–71.
   PubMed Web of Science ®Google Scholar
• Güzel-Akdemir Ö, Akdemir A, Pan P, et al. A class of sulfonamides with strong inhibitory action against the α-carbonic anhydrase from Trypanosoma cruzi. J Med Chem 2013;56:5773–81.
   PubMed Web of Science ®Google Scholar
• de Menezes Dda R, Calvet CM, Rodrigues GC, et al. Hydroxamic acid derivatives: a promising scaffold for rational compound optimization in Chagas disease. J Enzyme Inhib Med Chem 2016;31:964–73.
   PubMed Web of Science ®Google Scholar
• Rodrigues GC, Feijó DF, Bozza MT, et al. Design, synthesis, and evaluation of hydroxamic acid derivatives as promising agents for the management of Chagas disease. J Med Chem 2014;57:298–308.
   PubMed Web of Science ®Google Scholar
• Pan P, Vermelho AB, Scozzafava A, et al. Anion inhibition studies of the α-carbonic anhydrase from the protozoan pathogen Trypanosoma cruzi, the causative agent of Chagas disease. Bioorg Med Chem 2013;21:4472–6.
   PubMed Web of Science ®Google Scholar
• Garaj V, Puccetti L, Fasolis G, et al. Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX. Bioorg Med Chem Lett 2005;15:3102–8.
   PubMed Web of Science ®Google Scholar
• Zetasizer Nano. User manual. Malvern: Malvern Instruments. Man0485, n. 1.1, 2004. Available from: http://www.malvern.com/en/support/resource-center/usermanuals/MAN0485EN.aspx. [last accessed 20 Nov 2014].
   Google Scholar
• Aymerich S, Goldenberg S. The karyotype of Trypanosoma cruzi Dm 28c: comparison with other T. cruzi strains and trypanosomatids. Experiment Parasitol 1989;69:107–15.
   PubMed Web of Science ®Google Scholar
• Silva LHP, Nussenweig V. Sobre uma cepa de Trypanosoma cruzi altamente virulenta para o camundongo branco. [On a strain of Trypanosoma cruzi highly virulent for white mice]. V Fol Clin Biolog 1953;20:191–207.
   Google Scholar
• Alvarenga NJ, Bronfen E. Metaciclogênese do Trypano-soma cruzi como parâmetro de interação do parasita com o triatomíneo vetor. Ver Soc Bras Med Trop 1997;30:247–50.
   PubMedGoogle Scholar
• Rodrigues IA, Silva B, Santos ALS, et al. A new experimental culture medium for cultivation of Leishmania amazonensis: its efficacy for the continuous in vitro growth and differentiation of infective promastigote forms. Parasitology Res 2010;106:1249–52.
   PubMed Web of Science ®Google Scholar
• Rolon M, Vega C, Escario JA, et al. Development of resazurin microtiter assay for drug sensibility testing of Trypanosoma cruzi epimastigotes. Parasitol Res 2006;99:103–7.
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;983:55–63.
   Web of Science ®Google Scholar
• Romanha AJ, Castro SL, Soeiro MNC, et al. In vitro and in vivo experimental models for drug screening and development for Chagas disease. Mem Inst Oswaldo Cruz 2010;105:233–8.
   PubMed Web of Science ®Google Scholar